These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12051920)

  • 21. Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells.
    Röhn TA; Schadendorf D; Sun Y; Nguyen XD; Roeder D; Langen H; Vogt AB; Kropshofer H
    Eur J Immunol; 2005 Oct; 35(10):2826-39. PubMed ID: 16163671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope.
    Röhn TA; Reitz A; Paschen A; Nguyen XD; Schadendorf D; Vogt AB; Kropshofer H
    Cancer Res; 2005 Nov; 65(21):10068-78. PubMed ID: 16267033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
    Hasegawa K; Noguchi Y; Koizumi F; Uenaka A; Tanaka M; Shimono M; Nakamura H; Shiku H; Gnjatic S; Murphy R; Hiramatsu Y; Old LJ; Nakayama E
    Clin Cancer Res; 2006 Mar; 12(6):1921-7. PubMed ID: 16551878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
    Ebert LM; Liu YC; Clements CS; Robson NC; Jackson HM; Markby JL; Dimopoulos N; Tan BS; Luescher IF; Davis ID; Rossjohn J; Cebon J; Purcell AW; Chen W
    Cancer Res; 2009 Feb; 69(3):1046-54. PubMed ID: 19176376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells.
    Li Y; Depontieu FR; Sidney J; Salay TM; Engelhard VH; Hunt DF; Sette A; Topalian SL; Mariuzza RA
    J Mol Biol; 2010 Jun; 399(4):596-603. PubMed ID: 20417641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
    J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
    Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
    Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
    Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
    Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma.
    Murray JL; Gillogly M; Kawano K; Efferson CL; Lee JE; Ross M; Wang X; Ferrone S; Ioannides CG
    Cancer Res; 2004 Aug; 64(15):5481-8. PubMed ID: 15289358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
    Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
    Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen.
    Wang RF; Wang X; Atwood AC; Topalian SL; Rosenberg SA
    Science; 1999 May; 284(5418):1351-4. PubMed ID: 10334988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [MHC tetramers: tracking specific immunity].
    Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
    Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.
    Maccalli C; Di Cristanziano V; Fodale V; Corsi D; D'Agostino G; Petrangeli V; Laurenti L; Guida S; Mazzocchi A; Arienti F; Perrone MP; Castelli C; Rivoltini L; Zagonel V; Tartaglia M; Parmiani G; Belardelli F
    Clin Cancer Res; 2008 Nov; 14(22):7292-303. PubMed ID: 18974390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
    Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
    Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
    Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MHC Class II-Restricted Tumor Antigens Recognized by CD4+ T Cells: New Strategies for Cancer Vaccine Design.
    Zeng G
    J Immunother (1991); 2001 May; 24(3):195-204. PubMed ID: 11395634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Viral escape at the molecular level explained by quantitative T-cell receptor/peptide/MHC interactions and the crystal structure of a peptide/MHC complex.
    Tissot AC; Ciatto C; Mittl PR; Grütter MG; Plückthun A
    J Mol Biol; 2000 Sep; 302(4):873-85. PubMed ID: 10993729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ternary complex: T cell receptor, MHC protein, and immunogenic peptide.
    Rothbard JB
    Semin Immunol; 1990 Sep; 2(5):283-95. PubMed ID: 2134014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.